William Polvino
Direktor/Vorstandsmitglied bei SAB BIOTHERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Profil
William J.
Polvino is currently the Chief Executive Officer & Director at Bridge Medicines LLC since 2017.
He is also the Director at SAB Sciences, Inc. since 2019 and the Independent Director at SAB Biotherapeutics, Inc. since 2021.
Previously, Dr. Polvino served as the President & Chief Executive Officer at Sapphire Therapeutics, Inc. from 2002 to 2009 and at Veloxis Pharmaceuticals A from 2011 to 2015.
He also held positions at Helsinn Therapeutics (U.S.), Inc., Big Cypress Acquisition Corp., Merck & Co., Inc., and Innoviva, Inc.Dr. Polvino holds a doctorate degree from the University of Medicine & Dentistry of New Jersey and an undergraduate degree from Boston College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
13.05.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von William Polvino
Unternehmen | Position | Beginn |
---|---|---|
SAB BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 22.10.2021 |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Vorstandsvorsitzender | 27.03.2017 |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Direktor/Vorstandsmitglied | 01.01.2019 |
Ehemalige bekannte Positionen von William Polvino
Unternehmen | Position | Ende |
---|---|---|
VELOXIS PHARMACEUTICALS A/S | Vorstandsvorsitzender | 10.12.2015 |
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Präsident | 01.01.2009 |
BIG CYPR | Direktor/Vorstandsmitglied | - |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Vorstandsvorsitzender | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Ausbildung von William Polvino
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Boston College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
INNOVIVA, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
SAB BIOTHERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Health Technology |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Health Technology |
Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp. Financial ConglomeratesFinance Big Cypress Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on November 12, 2020 and is headquartered in Miami Beach, FL. | Finance |